KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Xenon Pharmaceuticals (XENE) over the last 13 years, with Q3 2025 value amounting to $6.1 million.

  • Xenon Pharmaceuticals' Change in Accured Expenses rose 43959.73% to $6.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.3 million, marking a year-over-year increase of 10098.97%. This contributed to the annual value of $8.5 million for FY2024, which is 11701.86% up from last year.
  • According to the latest figures from Q3 2025, Xenon Pharmaceuticals' Change in Accured Expenses is $6.1 million, which was up 43959.73% from $869000.0 recorded in Q2 2025.
  • Xenon Pharmaceuticals' Change in Accured Expenses' 5-year high stood at $9.2 million during Q2 2024, with a 5-year trough of -$5.8 million in Q1 2022.
  • Moreover, its 5-year median value for Change in Accured Expenses was $2.1 million (2022), whereas its average is $1.4 million.
  • In the last 5 years, Xenon Pharmaceuticals' Change in Accured Expenses skyrocketed by 87505.24% in 2021 and then tumbled by 74478.11% in 2024.
  • Over the past 5 years, Xenon Pharmaceuticals' Change in Accured Expenses (Quarter) stood at $3.8 million in 2021, then skyrocketed by 60.14% to $6.0 million in 2022, then plummeted by 61.76% to $2.3 million in 2023, then skyrocketed by 168.75% to $6.2 million in 2024, then decreased by 1.81% to $6.1 million in 2025.
  • Its Change in Accured Expenses stands at $6.1 million for Q3 2025, versus $869000.0 for Q2 2025 and -$3.8 million for Q1 2025.